Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01747746 · ClinicalTrials.gov registry record · Phase 4
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
A Phase 4 study, sponsored by Cook County Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT01747746 is a Phase 4 study that has completed, run by Cook County Health. The registered enrollment target is 33 participants.
The verdict
NCT01747746, a Phase 4 study, has completed, sponsored by Cook County Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
Interventions
- DRUG Rivaroxaban
- DRUG Warfarin and Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01747746
The ClinicalTrials.gov registry entry for NCT01747746 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook County Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban is the first listed.
NCT01747746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01747746 about?
NCT01747746 is a clinical study titled "Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study". The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
What is the current status of trial NCT01747746?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2012-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01747746?
The interventions under investigation include: Rivaroxaban (DRUG), Warfarin and Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT01747746?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.